Postural Control in Relapsing-Remitting Multiple Sclerosis [PDF]
International Archives of Otorhinolaryngology, 2022 Introduction Postural instability is considered one of the most disabling symptoms of relapsing-remitting multiple sclerosis (RRMS). Objective To evaluate postural control in patients with RRMS.
Flavia Salvaterra Cusin +5 more
doaj +3 more sources
Natalizumab for relapsing-remitting multiple sclerosis
Neurología (English Edition), 2011 Introduction: Natalizumab is a monoclonal antibody that inhibits leukocyte migration across the blood-brain barrier and has been approved for the treatment of relapsing-remitting multiple sclerosis.
A. Horga, M. Tintoré
doaj +3 more sources
Role of Diet and Supplementation with Omega-3 Polyunsaturated Fatty Acids for Managing Chronic Fatigue in Patients with Relapsing-Remitting Multiple Sclerosis [PDF]
Journal of Biomedical & Clinical Research, 2022 Multiple sclerosis (MS) is a chronic autoimmune demyelinating disease of the central nervous system (CNS) with unclear and multifactorial etiology, variable clinical symptoms with different severity, and treatment with limited efficacy.
Nicholas Shepherd +5 more
doaj +3 more sources
Positive correlation between functional disability, excessive daytime sleepiness, and fatigue in relapsing-remitting multiple sclerosis [PDF]
Arquivos de Neuro-Psiquiatria, 2016 Sleep disorders in patients with multiple sclerosis have various causes and interfere with daytime wakefulness. This study assessed the correlation between fatigue, excessive daytime sleepiness and level of disability.
Douglas Martins Braga +3 more
doaj +4 more sources
Tissue factor as a potential coagulative/vascular marker in relapsing-remitting multiple sclerosis
Frontiers in Immunology, 2023 ObjectivesRecent studies supported coagulation involvement in multiple sclerosis, an inflammatory-demyelinating and degenerative disease of the central nervous system. The main objectives of this observational study were to identify the most specific pro-
Tatiana Koudriavtseva +21 more
doaj +1 more source
Interferon in relapsing-remitting multiple sclerosis [PDF]
Cochrane Database of Systematic Reviews, 2001 Recombinant interferons have been shown to suppress both the clinical and magnetic resonance imaging (MRI) measures of disease activity in patients with relapsing remitting multiple sclerosis (RRMS).We performed a Cochrane review of all randomised, placebo-controlled trials of recombinant interferons in RRMS.Of 208 articles identified by a predefined ...
George PA Rice +7 more
openaire +3 more sources
Interferon-β induces hepatocyte growth factor in monocytes of multiple sclerosis patients. [PDF]
PLoS ONE, 2012 Interferon-β is a first-line therapy used to prevent relapses in relapsing-remitting multiple sclerosis. The clinical benefit of interferon-β in relapsing-remitting multiple sclerosis is attributed to its immunomodulatory effects on inflammatory ...
Nicolas Molnarfi +4 more
doaj +1 more source
Meta‐analysis of the use of Ofatumumab in the treatment of relapsing‐remitting multiple sclerosis
Medicine Advances, 2023 Background Ofatumumab is the first monoclonal antibody developed specifically for treating relapsed multiple sclerosis (RMS). This disease (Multiple Sclerosis) includes relapsing–remitting multiple sclerosis (RRMS), a chronic autoimmune illness that ...
Peter Olujimi Odutola +7 more
doaj +1 more source
Natalizumab for relapsing remitting multiple sclerosis [PDF]
Cochrane Database of Systematic Reviews, 2009 Natalizumab (NTZ) (Tysabri(®)) is a monoclonal antibody that inhibits leukocyte migration across the blood-brain barrier, thus reducing inflammation in central nervous system, and has been approved worldwide for the treatment of relapsing-remitting multiple sclerosis (RRMS).To evaluate the efficacy, tolerability and safety of NTZ in the treatment of ...
Pucci, Eugenio +6 more
openaire +4 more sources
Delayed P100-Like Latencies in Multiple Sclerosis: A Preliminary Investigation Using Visual Evoked Spread Spectrum Analysis. [PDF]
PLoS ONE, 2016 Conduction along the optic nerve is often slowed in multiple sclerosis (MS). This is typically assessed by measuring the latency of the P100 component of the Visual Evoked Potential (VEP) using electroencephalography.
Hanni S M Kiiski +15 more
doaj +1 more source